Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Oktober 2017 08:00 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting

- Interim phase 2 study results demonstrate the potential for superior efficacy and better tolerability over existing second-line therapy - CymaBay will also present new clinical research on...
18. September 2017 08:00 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Two Investor Conferences

NEWARK, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
11. September 2017 08:00 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis

NEWARK, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
15. August 2017 08:30 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology

NEWARK, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
10. August 2017 16:01 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update

NEWARK, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
07. August 2017 08:00 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10

NEWARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
24. Juli 2017 16:05 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEWARK, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
19. Juli 2017 08:30 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Announces Pricing of Public Offering of Common Stock

NEWARK, Calif., July 19, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
17. Juli 2017 16:14 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Announces Proposed Public Offering of Common Stock

NEWARK, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
17. Juli 2017 07:30 ET | Quelle: CymaBay Therapeutics, Inc.

CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

Strong reduction in alkaline phosphatase of 39% (5 mg) and 45% (10 mg) at week 12No safety signal for transaminase elevation or drug-induced itchPotential for superior efficacy and better tolerability...

Vorherige Seite